p21 peptides

/Home/Lyophilization and Protein Formulation Patents/Patent Articles - Lyophilization/Patent Pending - Lyophilization

United States Patent Application 20050153894
Kind Code A1
Zheleva, Daniella I. ; et al. July 14, 2005
p21 peptides
Abstract
The present invention relates to p21 derived peptides capable of inhibiting CDK/cyclin complexes, particularly cyclins A or E/CDK2, by modifying the interaction with their substrates. The peptides are derived from a C-terminal region of p21 and display selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Variants of such peptides particularly involving certain alanine replacements are shown to be particularly potent.
Inventors: Zheleva, Daniella I.; (Dundee, GB) ; Fischer, Peter Martin; (Angus, GB) ; Mclnnes, Campbell; (Dundee, GB) ; Andrews, Martin J.I.; (Dundee, GB) ; Chan, Weng C.; (Nottingham, GB) ; Atkinson, Gail E.; (Beverley, GB)
Correspondence Name and Address: LAHIVE & COCKFIELD, LLP.
28 STATE STREET
BOSTON
MA
02109
US
Assignee Name and Adress: Cyclacel Limited
London
GB

Serial No.: 771242
Series Code: 10
Filed: April 13, 2004
U.S. Current Class: 514/15; 530/329
U.S. Class at Publication: 514/015; 530/329
Intern'l Class: A61K 038/08; C07K 007/06